|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | IRCCS Burlo Garofolo |
|---|---|
| Information provided by: | IRCCS Burlo Garofolo |
| ClinicalTrials.gov Identifier: | NCT00382343 |
Purpose
The aim of this study is to assess the effectiveness of antibiotic prophylaxis in preventing pyelonephritis and in avoiding the appearance of new scars in a sample of children under 36 months with vesico-ureteral reflux (VUR).
| Condition | Intervention | Phase |
|---|---|---|
|
Pyelonephritis Renal Scars |
Drug: sulfamethoxazole/trimethoprim or nitrofurantoin prophylaxis |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Antibiotic Prophylaxis After Acute Pyelonephritis for Prevention of Urinary Tract Infections in Children With Vesico-Ureteral Reflux. |
| Estimated Enrollment: | 96 |
| Study Start Date: | November 1999 |
| Estimated Study Completion Date: | May 2006 |
In recent years, the effectiveness of continuous antibiotic prophylaxis in children with vesico-ureteral reflux (VUR) has been intensely discussed. The question is not only whether antibiotics are effective in preventing recurrent urinary tract infections (UTI), but also whether they alter the natural history of disease and help to prevent the appearance of new kidneys scars. The evidence on the effectiveness of antibiotic prophylaxis is scanty: randomised controlled trials (RCT) published until now are poorly designed and carried out in very heterogeneous samples of children, i.e. spanning from 6 months to 14-18 years of age and pooling patients with and without VUR. A recently updated Cochrane Systematic Review concludes that high quality RCTs are needed to determine the effectiveness of long-term antibiotics for the prevention of UTIs in susceptible children. Moreover, the presence of VUR has not been firmly shown to be a risk factor for recurrence of pyelonephritis, and a direct association between VUR and the presence of scars or the appearance of new scars has not been demonstrated; there is just an association between VUR of grade IV-V and prenatal renal dysplasia, almost exclusively in male infants. In spite of this uncertainty, several practice guidelines recommend long term antibiotic prophylaxis in children with different degrees of VUR.
The aim of this study is to assess the effectiveness of antibiotic prophylaxis in preventing pyelonephritis and in avoiding the appearance of new scars in a sample of children under 36 months with VUR.
Comparison: In a multicentre trial, 100 patients with VUR diagnosed with cystourethrography after a first episode of acute pyelonephritis or for prenatal evidence of pyelectasia will be assigned randomly to receive prophylaxis or not. Randomization will be carried out using a centralized minimization procedure to balance for sex, age group and VUR grade.
Eligibility| Ages Eligible for Study: | up to 30 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Italy | |
| Sant'Orsola Hospital | |
| Bologna, Italy, 48138 | |
| Bufalini Hospital | |
| Cesena, Italy, 47023 | |
| Santa Maria degli Angeli Hospital | |
| Pordenone, Italy, 33170 | |
| Institute of Child Health IRCCS Burlo Garofolo | |
| Trieste, Italy, 34137 | |
| Italy, Gorizia | |
| San Polo Hospital | |
| Monfalcone, Gorizia, Italy, 34170 | |
| Italy, Udine | |
| Sant'Antonio Abate Hospital | |
| Tolmezzo, Udine, Italy, 33028 | |
| San Daniele Hospital | |
| San Daniele, Udine, Italy, 33100 | |
| Principal Investigator: | Marco Pennesi, MD | Institute of Child Health IRCCS Burlo Garofolo, Trieste, Italy |
More Information
| Study ID Numbers: | RC 35/00 |
| Study First Received: | September 28, 2006 |
| Last Updated: | September 28, 2006 |
| ClinicalTrials.gov Identifier: | NCT00382343 History of Changes |
| Health Authority: | Italy: Ministry of Health |
|
Prevention Pyelonephritis Renal scars Vesico-ureteral reflux Dimercaptosuccinic acid renal scan (DMSA) |
|
Trimethoprim-Sulfamethoxazole Combination Anti-Infective Agents Trimethoprim Antiprotozoal Agents Molecular Mechanisms of Pharmacological Action Pyelonephritis Urinary Tract Infections Infection Renal Agents Pyelitis Anti-Bacterial Agents Vesico-Ureteral Reflux Antimalarials |
Antiparasitic Agents Nitrofurantoin Urologic Diseases Therapeutic Uses Kidney Diseases Sulfamethoxazole Nephritis, Interstitial Urinary Bladder Diseases Anti-Infective Agents, Urinary Enzyme Inhibitors Folic Acid Antagonists Pharmacologic Actions Nephritis |